Other functions - preclinical efficacy and intermediate endpoint biomarkers
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Fox Chase Cancer Center
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $547,860
Award facts
- Opportunity
-
- N01CN2500278 Solicitation number
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Feb 27, 2012
- Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Dec 15, 2011
- Contract value 100% obligated
- $547,860.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Philadelphia, PA 19111, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $547,860 |
About this award
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy testing and biomarker analysis services for evaluating candidate cancer preventive therapies. The contract does not have a set-aside designation. The Institute for Cancer Research has previously served as a subcontractor on federal grants and contracts, contributing specialized cancer research capabilities. This particular delivery order is focused on continued evaluation of chemopreventive and immunopreventive regimens.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 21, 2012.
How much is contract HHSN26100002 worth?
The government has obligated $547,860 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201200015I, an indefinite delivery contract, on Preclinical Efficacy and Intermediate Endpoint Biomarkers.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award